Teva Pharmaceutical Industries (TEVA) Assets (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Assets for 18 consecutive years, with $39.9 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Assets fell 0.68% year-over-year to $39.9 billion; the trailing twelve-month figure through Jun 2026 stood at $39.9 billion (down 0.68% YoY), and the FY2025 full-year result was $40.7 billion, up 3.62% from the prior year.
• Assets held at $39.9 billion in Q2 2026 per TEVA's latest filing, from $40.0 billion in the prior quarter.
• Across five years, Assets topped out at $47.1 billion in Q1 2022 and bottomed at $38.4 billion in Q1 2025.
• Historically, Assets has averaged $42.1 billion across 5 years, with a median of $41.9 billion in 2023.
• The sharpest annual moves came in 2025 and 2026: Assets retreated 10.19% in 2025, then grew 4.23% in 2026.
• Over 5 years, Assets stood at $44.0 billion in 2022, then decreased by 1.21% to $43.5 billion in 2023, then decreased by 9.55% to $39.3 billion in 2024, then gained by 3.62% to $40.7 billion in 2025, then dropped by 2.19% to $39.9 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $39.9 billion, $40.0 billion, and $40.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.